Introduction
============

Total knee arthroplasty (TKA) is one of the most effective treatments of end-stage knee arthritis. The number of patients who will likely require TKA is expected to increase substantially in the near future due to the growing aging population[@b1-ksrr-30-142]. Outcomes following TKA are excellent in the majority of patients who undergo the procedure. Perhaps the most challenging complication following TKA is periprosthetic joint infection. Several methods and studies have been conducted to prevent infection following TKA. The use of laminar flow rooms, proper skin preparation, limits on operating room traffic, administration of appropriate antibiotics prior to surgical incision, and the use of various wound closure techniques can help to decrease infection rates[@b2-ksrr-30-142].

Taurolidine is an antimicrobial agent often used in experimental and clinical studies to prevent intra-abdominal adhesion formation and sepsis[@b3-ksrr-30-142]. It was initially used for its anti-inflammatory and antimicrobial properties in the treatment of surgical and wound infections, as well as for preventing infections stemming from the use of central venous catheters[@b4-ksrr-30-142]--[@b6-ksrr-30-142]. Taurolidine is also known to reduce thrombus weight[@b3-ksrr-30-142]. Furthermore, it seems to have a direct effect on tumor cells with a consecutive inhibition of cell growth[@b7-ksrr-30-142]--[@b9-ksrr-30-142]. However, there are few studies on the effects of taurolidine in orthopedic surgery. In particular, there has been no study conducted regarding whether taurolidine can reduce the risk of infection after TKA.

The purpose of the current study was to determine whether taurolidine could affect infection rates and inflammatory marker changes after TKA.

Materials and Methods
=====================

A total of 600 patients, (300 in the taurolidine irrigation group and 300 in the control group) who had been treated by a unilateral primary cemented TKA due to primary osteoarthritis of the knee in the period from January 2015 to March 2017, were retrospectively included in the study ([Fig. 1](#f1-ksrr-30-142){ref-type="fig"}). We used taurolidine until May 2016 and have not used it since in TKA patients. The taurolidine irrigation group was irrigated after implantation with a mix of 250 mL of taurolidine (taurolidine injection 2%, Samjin, Seoul, Korea) and 750 mL of normal saline. The control group was not irrigated after implantation. Inclusion criteria were patients with grade 3 or 4 osteoarthritis of the knee. Exclusion criteria were the absence of written informed consent, bilateral arthroplasties, complicated primary TKA with previous osteotomy, simultaneous fracture fixation, implant removal or bone grafting, thromboembolic diseases, presence of clotting disorder or current treatment with an antiplatelet agent, renal disease, and/or a history of allergy to taurolidine. All arthroplasties were performed through the medial parapatellar approach with the use of a tourniquet, a posterior-stabilized implant, a bone plug in the intramedullary canal, cementation, hemostasis with a tourniquet on, a compression bandage, suction pressure drainage for 48 hours, and a foot pump for deep vein thrombosis prophylaxis. All of the patients were given three doses of first-generation cephalosporin (one within 30 minutes before the procedure, and two doses at 12-hour intervals postoperatively). The primary outcome measures were erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). We evaluated the levels of CRP and ESR 3, 6, 13, and 20 days postoperatively. Previous studies have reported that plasma CRP levels in TKA patients increase rapidly after operation reaching maximum values within 2--3 days, after which they decrease rapidly[@b10-ksrr-30-142]--[@b14-ksrr-30-142]. Secondary outcome measures included periprosthetic joint infection.

Differences between the two groups were analyzed with the Student *t*-test for continuous variables and Pearson chi-square test or Fisher exact test for categorical variables. The mean changes in each group were analyzed with the independent *t*-test. Statistical analyses were performed with the IBM SPSS ver. 20.0 (IBM Co., Armonk, NY, USA). p\<0.05 were considered statistically significant.

Results
=======

The patients' mean age was 70.2 years in the taurolidine irrigation group and 71.2 years in the control group. There were no other significant differences between the two groups in terms of the considered baseline characteristics, including body weight, height, body mass index, and operation time ([Table 1](#t1-ksrr-30-142){ref-type="table"}). On the outcome measures, the taurolidine irrigation group had a significantly lower CRP (5.39 mg/dL vs. 7.55 mg/dL; p\<0.001) and ESR (53.21 mm/hr vs. 58.74 mm/hr; p=0.003) on postoperative day 3 in primary TKA. However, the taurolidine irrigation was not helpful to reduce CRP and ESR on postoperative days 6, 13, and 20. Periprosthetic joint infection occurred in only one patient in the taurolidine irrigation group, showing no statistical significance ([Table 2](#t2-ksrr-30-142){ref-type="table"}).

Discussion
==========

Infection is one of the most devastating complications following TKA, occurring in 1.55% of patients with Medicare within the first two postoperative years, and demonstrating a further incidence of 0.46% between postoperative years two and ten[@b15-ksrr-30-142]. In our study, one patient in the taurolidine group had a periprosthetic joint infection and there was no infection in the control group.

The diagnosis of infection after arthroplasty is quite difficult. Clinical, radiological and scintillographic findings and laboratory determinations of plasma CRP levels and ESRs are valuable in the diagnosis of infection and in the selection of appropriate treatment. Postoperatively, studies have proven the benefits of using CRP and ESR in the diagnosis of periprosthetic joint infection[@b16-ksrr-30-142]. Serological inflammatory markers, specifically ESR and CRP, are often used as initial tests, even when there is a low suspicion of periprosthetic joint infection[@b17-ksrr-30-142]. They are also commonly used in monitoring patient responses to therapy since they are inexpensive, non-invasive, and widely available.

Taurolidine was synthesized in the 1970s and was originally used as an antibiotic in the prophylactic treatment of intraperitoneal bacterial infections in patients with established peritonitis[@b18-ksrr-30-142],[@b19-ksrr-30-142]. Intraoperative and early postoperative local application of taurolidine, in addition to appropriate surgical treatment and postoperative care, has an important role in the prevention of postoperative septic complications, and has been found to decrease the potential for postoperative mortality[@b20-ksrr-30-142]. The utility of taurolidine as an antitumor agent has been investigated extensively recently[@b21-ksrr-30-142].

Taurolidine \[bis (1,1-dioxo-perhydro-1, 2, 4-thiadiazinyl-4) methane\] is a broad spectrum, non-antibiotic antimicrobial agent derived chemically from the aminosulfonic acid, taurine. The antimicrobial activity of taurolidine is considered to be due to the delivery of biologically active methylol taurinamide components that react via methylene iminium ions with cell wall constituents of bacteria[@b22-ksrr-30-142].

Taurolidine has a unique spectrum of antimicrobial activity, including gram-positive and gram-negative bacteria and fungi[@b23-ksrr-30-142],[@b24-ksrr-30-142]. Taurolidine demonstrates a bactericidal mode of action against a wide range of bacterial species, such as *Staphylococcus aureus* (*S. aureus*), *Staphylococcus epidermidis* (*S. epidermidis*), *Bacteroides fragilis*, and group C *Streptococci*[@b25-ksrr-30-142],[@b26-ksrr-30-142]. Taurolidine has been used for a long time in abdominal infections, in lung infections, and in dentistry[@b27-ksrr-30-142]. The most common organisms that cause infection after TKA are *S. aureus*, *S. epidermidis*, and *Streptococcus* species. Therefore, we supposed that taurolidine may contribute some to reducing the risk of infection after TKA.

Our present study showed that taurolidine irrigation was effective in lowering CRP (5.39 mg/dL vs. 7.55 mg/dL) and ESR (53.21 mm/hr vs. 58.74 mm/hr) on postoperative day 3 in primary TKA. This suggests that taurolidine irrigation is effective in lowering inflammation by postoperative day 3. However, taurolidine irrigation was not helpful to reduce CRP and ESR on postoperative days 6, 13, and 20. Additionally, there was one case of infection in the taurolidine irrigation group, and no case of infection in the control group, showing no statistically significant difference.

Several limitations exist in this study. First, this study included a small number of subjects. Second, this is a retrospective study based on the review of past medical records, so we do not know what information was not recorded. Third, the follow-up period of this study was too short. Finally, there may be multiple causes, which can have complex effects on the CRP level.

Conclusions
===========

The present study shows that taurolidine irrigation is effective in reducing CRP and ESR levels on postoperative day 3 in primary TKA. However, taurolidine irrigation was not helpful to reduce CRP and ESR on postoperative days 6, 13, and 20. Therefore, we believe that it is not necessary to use taurolidine for patients who undergo primary TKA.
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###### 

Baseline Characteristics

  Characteristic         Taurolidine group (n=300)   Control group (n=300)   p-value
  ---------------------- --------------------------- ----------------------- ---------
  Age (yr)               70.2±8                      71.2±8                  0.070
  Sex (F)                68.4                        69.1                    0.693
  Body weight (kg)       66.1±11.7                   67.3±11.5               0.502
  Height (m)             1.55±0.08                   1.56±0.09               0.902
  BMI (kg/m^2^)          26.6±4.1                    27.3±4.3                0.289
  Operation time (min)   91±15                       92±12                   0.494

Values are presented as mean±standard deviation or percentage.

BMI: body mass index.

###### 

Outcome Measures

  Variable      Taurolidine group (n=300)   Control group (n=300)   p-value
  ------------- --------------------------- ----------------------- ---------
  CRP (mg/dL)                                                       
   POD 3        5.39±3.57                   7.55±3.94               \<0.001
   POD 6        2.81±2.41                   2.60±2.32               0.29
   POD 13       0.96±1.29                   0.90±1.73               0.66
   POD 20       0.82±0.94                   0.90±1.73               0.79
  ESR (mm/hr)                                                       
   POD 3        53.21±20.22                 58.74±24.81             0.003
   POD 6        59.17±26.39                 58.11±21.96             0.59
   POD 13       45.55±21.43                 41.36±19.84             0.01
   POD 20       42.68±22.99                 44.19±24.39             0.77
  Infection     1                           0                       0.32

Values are presented as mean±standard deviation.

CRP: C-reactive protein, POD: postoperative day, ESR: erythrocyte sedimentation rate.
